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 Abstract 
 
Background. The Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP³S-)tool 
was recently developed to screen for potentially inappropriate prescribing (PIP).  
Objective. We aim (1) to determine PIP prevalence in older nursing home (NH) residents with 
polypharmacy using the GheOP³S-tool and (2) to identify those PIPs that are most frequently 
detected. 
Method. A cross-sectional study was carried out between February and June 2014 in 10 NHs in 
Belgium, supplied by a community pharmacy chain. For each NH, 40 residents (≥70 years, using ≥5 
chronic drugs) were included. PIP prevalence was determined using the GheOP³S-tool. 
Results. 400 NH residents were included [mean age (±SD): 86.2 (±6.3) years; median number of drugs 
(±IQR): 10 (7-12)]. A total of 1728 PIPs were detected in 387 (97%) participants (Median: 4; IQR: 2-6). 
The most prevalent items can be assigned to three categories: long-term use of central nervous 
system drugs (i.e. benzodiazepines, antidepressants and antipsychotics), use of anticholinergic drugs 
(mutual combinations and with underlying constipation/dementia) and underuse of osteoporosis 
prophylaxis. 
Conclusion. Screening for PIP by means of the GheOP³S-tool revealed a high prevalence of PIP among 
older NH residents with polypharmacy. This finding urges for initiatives on the patient-level, but also 
on a broader, institutional level.   
 
IMPACT OF FINDINGS FOR PROFESSIONALS 
- The prevalence of potentially inappropriate prescribing in Belgian nursing homes is high. 
- The most prevalent PIP-items can be assigned to the following three main categories: long-
term use of drugs that influence the central nervous system, use of anticholinergic drugs and 
underuse of osteoporosis prophylaxis. These issues should therefore be targeted first. 
- A GheOP³S-tool screening could be part of a periodic evaluation of nursing home residents’ 
medication or, on the institutionalized level, serve as benchmarking for the quality of 
prescribing. 
 INTRODUCTION 
Nursing home residents are particularly vulnerable to (potentially) inappropriate prescribing 
((P)IP) as they are more fragile, receive therapy from multiple health care workers and are often 
prescribed a high number of drugs(1). It makes prescribing in this setting a complex and challenging 
task(2, 3).  Additionally, PIP (i.e. overuse, underuse and misuse of drugs) is often associated with 
increased prevalence of adverse drug events (ADEs) and health care utilization(4). Other health care 
professionals such as pharmacists and nurses, could assist physicians in the medication management 
process to ensure the most effective and safe pharmacotherapy for the patient(5).  
Screening of medication by pharmacists, preferably as a part of a full medication review with 
multidisciplinary consultation, is a proposed strategy to improve the appropriateness of 
prescribing(1, 6, 7) and has been shown to be effective (5). However, significant improvements on 
hospitalizations or mortality are currently lacking(7). This is probably due to the use of inappropriate 
outcome measures (i.e. number of drugs, MMSE-improvement etc), a lack of power to detect 
statistically significant differences or – most importantly – the poor acceptance rate and continuation 
of recommendations resulting from the reviews(5, 8). Additionally, there exist practical barriers to 
the systematic performance of a medication review among nursing home residents. This includes the 
lack of pharmacists with specific training in geriatric pharmacotherapy, the lack of centralized 
medical records and insufficient computerized support(8).  
Recently, we developed the Ghent Older People’s Prescriptions community Pharmacy 
Screening (GheOP³S-) tool, an explicit screening tool to detect PIPs with high clinical relevance for 
older patients(9). This screening tool provides the community pharmacist with the possibility to 
initiate a medication review process in a systematic and straightforward way, solely based on 
medication dispensing data available in the community pharmacy. Ideally, the results of a medication 
screening with the GheOP³S-tool should be discussed with the prescribing physician to confirm 
clinical relevance for the specific patient. Based on the outcomes of the pharmacist-physician 
consultation, suggestions for medication changes are proposed. Lastly, these suggestions are to be 
discussed with the patient, and a final treatment plan is to be decided on.  
 AIM OF THE STUDY 
The GheOP³S-tool has already been tested in ambulatory patients(10), where it showed to 
detect all three categories of PIP: overuse, misuse and underuse. In the current observational study, 
we aim to perform a screening for PIP in nursing home residents using the GheOP³S-tool and to 
identify those PIPs that are most frequently detected. 
 
ETHICS APPROVAL 
Ethics approval was received of the Ethics Committee of the Ghent University Hospital.  
 
METHOD 
This manuscript describes a cross-sectional study, carried out between February and June 
2014, in 10 nursing homes in Flanders (i.e. the Dutch speaking part of Belgium) supplied by a 
community pharmacy chain. The pharmacy chain provided the research centre with an anonymized 
dataset, previously set up to examine problems for robotic unit dose drug dispensing. This database 
was set up as follows: 10 nursing homes were randomly selected out of a sample of 33 nursing 
homes which are all supplied by the community pharmacy chain. From each selected nursing home, 
forty residents meeting the following inclusion criteria were randomly selected: (1) aged 70 years or 
older and (2) using 5 of more chronic (i.e. according to a set regimen) drugs registered in the Belgian 
Commented Drugs Repertory(11). The dataset contained the residents’ medication records and basic 
demographics (age & gender). Each drug was assigned a seven-digit code in accordance with the 
Anatomical Therapeutic Chemical (ATC) Classification System formulated by the World Health 
Organization Collaborating Centre for Drug Statistics Methodology(12).  
 We applied the GheOP³S-tool(9) to the patients’ chronic medication in the received dataset. 
The choice to use this screening-tool was deliberate. First, the GheOP³S-tool makes it possible to 
screen for PIP in settings where clinical data are not available. Second, the GheOP³S-tool is adapted 
to the European market and addresses all types of PIP. Third, the GheOP³S-tool offers the 
pharmacists a backbone to get started with the process of a medication review. An elaborate 
document describing rationale, alternative treatment plans and scientific background information 
empowers the pharmacists to initiate pharmacist-physician contacts to discuss the considered 
clinically relevant PIP-items. The GheOP³S-tool consists of 83 items, categorized in 5 different parts 
(Part 1: Potentially inappropriate drugs, independent of diagnosis, Part 2: Potentially inappropriate 
drugs, dependent on diagnosis, Part 3: Potential Prescribing Omissions (PPOs), Part 4: Drug Drug 
Interactions (DDIs) of specific relevance and Part 5: General care-related items to be addressed in the 
community pharmacy). Part 5 of the GheOP³S-tool was not applied in the current study as this part 
reflects on pharmacy work processes and is not applicable to the bulk supplying for nursing homes. 
With regard to the diagnoses in Part 2, drug proxies were used. Only diagnoses that unambiguously 
could be derived from the patient’s medication (e.g. diabetes from insulin, gout from allopurinol, etc) 
were taken into account. We also identified the GheOP³S-criteria that accounted for the highest 
proportion of PIP. The PIP screening with the GheOP³S-tool was performed manually by 3 
researchers (EP, CVD and KM) and double-checked by the main investigator (ET). The STROBE 
standardized reporting guidelines for cross-sectional studies were followed to ensure the uniform 
conduct and reporting of the research(13). 
Descriptives were displayed as counts with percentages and means with standard deviations 
or medians with interquartile ranges as appropriate. The PIP prevalence is represented as the 
proportion of residents with at least one PIP and the median number of PIPs per resident. 
 
RESULTS 
The 400 randomly included residents had a mean age (± SD) of 86.2 (±6.3) years with 63% of 
residents (250) being older than 85 years. Three quarters (298 residents) of the population was 
female. The total number of medicines taken was 4079, with an absolute range varying between 5 to 
34 drugs per resident and a median of 10 per resident (Interquartile Range (IQR): 7-12). 
Considering Part 1 to Part 4 of the GheOP³S-tool, a total of 1728 PIPs were detected in 387 
(97%) participants (Median: 4; IQR: 2-6). Figure 1 represents the distribution of number of PIPs 
detected per patient according to the full GheOP³S-tool, as well as according to each part of the tool. 
All types of PIP (overuse, underuse and misuse) are detected. The 5 most prevalent items for each 
part of the GheOP³S-tool are reported in Table 1. The items of Part 2 and Part 3 are displayed in two 
ways; relative to the total population and relative to the overall drug or disease prevalence. A 
complete list of the prevalence of all individual GheOP³S-criteria is reported as Online Supplement.  
 
 Figure 1: Distribution of the number of PIP-items detected per patient, using the GheOP³S-tool (n = 400; Part 1: Potentially 
inappropriate drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: 
Potential prescribing omissions and Part 4: Drug-drug interactions of specific relevance)
 Table 1: Most prevalent GheOP³S-criteria of each part of the GheOP³S-tool, n = 400 
 GheOP³S-criterion N, % (relative 
to total 
population)  
N, % (relative 
to overall drug 
or disease 
prevalence) 
Part 1: Potentially inappropriate drugs, independent of diagnosis 341 (85%)  
1 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days OR Any short- or long-acting benzodiazepine 
212 (53%)  
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
195 (49%)  
 Any short- or long-acting benzodiazepine 35 (9%)  
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days AND Any short- or long-acting benzodiazepine 
18 (5%)  
2 Any antidepressant ≥1 year 169 (42%)  
3 Any antipsychotic drug ≥1 month 117 (29%)  
4 Any PPI at full dose ≥8 weeks 73 (18%)  
5 Any oral non-steroidal anti-inflammatory drug 35 (9%)  
Part 2: Potentially inappropriate drugs, dependent on diagnosis  219 (55%)  
1 Anticholinergics with constipation 149 (37%) 149/199 (75%) 
2 Calcium channel blockers with constipation 43 (11%) 43/197 (22%) 
3 Anticholinergics with dementia or cognitive impairment 36 (9%) 36/51 (71%) 
4 Oral corticosteroids >1 week with hypertension 19 (5%) 19/221 (9%) 
5 Thiazide and loop diuretics with gout 18 (5%) 18/27 (67%) 
Part 3: Potential prescribing omissions 245 (61%)  
1 The patient has an elevated risk for osteoporosis and is not prescribed Calcium 
and Vitamin D supplementation. 
214 (54%) 214/295 (73%) 
2 The patient is taking narcotic analgesics and is not prescribed appropriate 
preventative bowel regimen. 
35 (9%) 35/84 (42%) 
3 The patient is taking oral corticosteroids for ≥1 month and is not prescribed a 
Calcium and Vitamin D supplementation. 
15 (4%) 15/25 (60%) 
4 The patient is taking an equivalent of 7.5 mg of oral prednisone or more for ≥3 
months and is not prescribed calcium/Vitamin D supplementation and 
bisphosphonates. 
7 (2%) 7/11 (64%) 
5 The patient is taking methotrexate and is not prescribed folic acid 1 (0%) 1/1 (100%) 
supplementation. 
Part 4: Drug-drug interactions of specific relevance 230 (58%)  
1 Any combination of anticholinergic drug 163 (41%)  
2 Oral antidiabetics/insulin and β-blocker 41 (10%)  
 Oral antidiabetics/insulin and non-selective β-blocker 8 (2%)  
 Oral antidiabetics/insulin and selective β-blocker 37 (9%)  
3 Oral non-steroidal anti-inflammatory drug and diuretic 22 (6%)  
4 Bisphosphonate and calcium, magnesium, zinc, iron or aluminium 22 (6%)  
5 RAAS inhibitor and potassium sparing diuretic, potassium supplements or 
potassium containing drugs 
20 (5%)  
RAAS: Renin angiontensin aldosteron system 
 
DISCUSSION 
In this observational study, we detected at least one PIP in 97% of the 400 randomly included 
nursing home residents, with a median of 4 PIPs per resident. This is in concordance with two other 
Belgian studies and with studies from other European countries(3, 5, 14, 15). Some studies report 
lower prevalence rates, however in these cases, the researchers evaluated PIP with a smaller subset 
of published criteria or only screened for one aspect of PIP (e.g. underuse)(16, 17). On the other 
hand, compared with a recent systematic review, estimating PIP prevalence in the ambulatory 
setting(18), the prevalence in nursing homes is markedly higher. Although, one previously performed 
study with the GheOP³S-tool in the ambulatory setting observed a comparable PIP prevalence (at 
least one PIP in 97% of patients, median of 3 PIP per patient)(10).  
The fact that nearly all patients had at least one PIP shows that there is a large room for 
improvement on the appropriateness of prescribing. During the development of the GheOP³S-tool, 
the experts unanimously agreed on the clinical relevance of screening for all included items in older 
patients in general. Whether the detected problems are also clinically relevant for the individual 
patient, still needs to be assessed during a pharmacist-physician consultation and agreement. The 
actual rate of inappropriate prescribing will therefore probably be somewhat lower. 
The most prevalent PIP-items identified by the GheOP³s-tool can be assigned to the following 
three main categories: long-term use of drugs that influence the central nervous system (i.e. 
hypnosedatives, antidepressants and antipsychotics), use of anticholinergic drugs (mutual 
combinations and with underlying constipation or dementia) and underuse of osteoporosis 
prophylaxis. Additionally, the use of systemic NSAIDs and the long-term use of high-dose PPIs is 
frequent in this population. All of these items are also mentioned by other European observational 
studies(2, 8, 19). In the observational study, using the GheOP³S-tool in the ambulatory setting, the 
same items (except for the use of anticholinergic drugs) significantly added to the number of PIP(10). 
As the use of drugs that influence the central nervous system and drugs with anticholinergic effects 
significantly adds to the high number of PIP, with possible significant clinical consequences as a 
result, the inappropriate use of these drug classes should be targeted first. Multiple trials already 
addressed these specific issues and showed that deprescribing in nursing homes is possible, improves 
the quality of prescribing and has a positive effect on the quality of life of the patient.  
One example is the study be Bourgeois et al(20), in which 66% of chronic benzodiazepine 
users were successfully discontinued after 8 months, with an improved self-perceived sleep quality 
and significantly less midnight awakenings(20). Another example, a randomized controlled trial 
performed in 22 nursing homes, showed that the anticholinergic burden was significantly reduced by 
a pharmacist-initiated medication review(21).  
Despite the fact that the GheOP³S-tool was developed to detect PIP on the patient level, this 
study also shows that an overall analysis, applied to all residents of one institution, could expose the 
most urgent issues on a more general level. This way, the GheOP³S-tool might serve as a 
benchmarking instrument for the prescribing behaviour in a nursing home. The result of such an 
overall analysis would be the ideal starting point for interdisciplinary case-conferences or the basis 
for targeted action plans. Using the GheOP³S-tool, the dispensing pharmacist is able to assist 
prescribers and the nursing home management to increase the quality of prescribing. 
 
Strengths and limitations 
This study shows that the recently developed GheOP³S-tool, a validated community 
pharmacy specific list where limited clinical data are available, is practical and straightforward in 
screening for PIPs in nursing home residents. This study has nevertheless some limitations. As the 
GheOP³S-tool is explicit of nature, it does not take into account all patient factors in evaluating the 
pharmacotherapy, e.g. diagnoses, patient preferences or earlier attempts to tackle PIP. Also, some 
relevant items might have been missed. To tackle this, a future study will compare a GheOP³s-
screening with a full medication review. This way, the items that are systematically missed will be 
identified and added to the GheOP³S-tool in a future update. Additionally, there were no pharmacist-
prescriber contacts to discuss the clinical relevance of the detected items. E.g. the clinical relevance 
of the interaction between a selective β-blocker and oral antidiabetics/insulin is minimal if glycemic 
control is good. Also, it is difficult to estimate generalizability to other countries as prescribing 
behavior can largely differ between geographical regions. Despite the fact that our results match 
findings from other European countries, it would still be interesting to compare our results to a 
GheOP³S-tool application in other European countries.  
 
CONCLUSION 
Screening for PIP by means of the GheOP³S-tool showed a high PIP prevalence in older 
nursing home residents with polypharmacy. This urges for initiatives on the patient-level, but also on 
a broader, institutional level.  The GheOP³S-tool could be part of such an evaluation process in which 
it could be the starting point for multidisciplinary interventions, initiated by the pharmacist. Such a 
process aims to improve the quality of prescribing for nursing home residents with polypharmacy.   
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 Online Supplement: 
Supplement Table: Full list of prevalence of all GheOP³S-criteria 
No. GheOP³S-criterion N, % (relative to 
total population, 
n=400)  
N, % (relative to 
overall drug or 
disease 
prevalence) 
Part 1b: Potentially inappropriate drugs, independent of diagnosis – Drug classes 
1 Any antidepressant ≥1year 169 42%  
2 Any antipsychotic drug ≥1 month 117 29%  
3 Any drug for arterial vascular disorders  9 2%  
4 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
195 49%  
5 Any short  or long-acting benzodiazepine  
 
35 9%  
6 Any long-acting sulfonylurea derivative  18 5%  
7 Any nasal vasoconstrictor ≥1 month 3 1%  
8 Any oral NSAID 35 9%  
9 Any PPI at full dosea ≥8 weeks  73 18%  
10 Any recently marketed drug (black triangles) 13 3%  
11 Any sedating antihistaminic drug  14 4%  
Part 1b: Potentially inappropriate drugs, independent of diagnosis - Specific molecules 
12 Alizapride 5 1%  
13 Bisacodyl 5 1%  
14 Clonidine 3 1%  
15 Codeine and its derivatives for acute cough 6 2%  
16 Dabigatran 3 1%  
17 Digoxin >0,125mg/day 8 2%  
18 Dipyridamole monotherapy (without ASA) 0 0%  
19 Ginkgo biloba or Panax ginseng 3 1%  
20 Liquid paraffin 1 0%  
21 Methyldopa  0 0%  
22 Metoclopramide 13 3%  
23 Pentazocine 0 0%  
24 Phenobarbital 1 0%  
25 Pseudoephedrine oral 0 0%  
26 Rivaroxaban or Apixaban 10 3%  
27 Senna glycosides 1 0%  
28 Picosulfate 4 1%  
29 Theophylline 10 3%  
30 Ticlopidine, new prescription 0 0%  
31 Tramadol, new prescription 30 8%  
Part 2a: Potentially inappropriate drugs, dependent on diagnosis - Drug classes 
32 Any  antipsychotic other than quetiapine and clozapine with Parkinson’s disease 13 3% 13/54 (24%) 
33 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with dementia or cognitive impairment 
36 9% 36/51 (71%) 
34 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with constipation 
149 37% 149/199 (75%) 
35 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with BPH 
13 3% 13/21 (62%) 
36 Calcium Channel Blockers with constipation 43 11% 43/197 (22%) 
37 Non-selective beta-blockers with asthma or COPD 9 2% 9/90 (10%) 
38 Oral corticosteroids >1 week with diabetes 8 2% 8/103 (8%) 
39 Oral corticosteroids >1 week with hypertension 19 5% 19/221 (9%) 
40 Thiazide and loop diuretics with gout 18 5% 18/27 (67%) 
Part 2b: Potentially inappropriate drugs, dependent on diagnosis - Specific molecules 
41 Alizapride with Parkinson’s disease 0 0% 0/54 (0%) 
42 Metoclopramide with Parkinson’s disease 0 0% 0/54 (0%) 
Part 3: Potential prescribing omissions  
43 The patient is taking ≥ an equivalent of 7.5 mg of oral prednisone for ≥3 months and is not 
prescribed Ca/VitD supplementation and bisphosphonates. 
7 2% 7/11 (64%) 
44 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen (preferably macrogol or lactulose). 
35 8% 35/84 (42%) 
45 The patient has an elevated risk for osteoporosis (determined via FRAX-tool(22)) and is not 
prescribed Calcium/Vitamin D supplementation. 
214 54% 214/295 (73%) 
46 The patient is taking oral corticosteroids for ≥1 month and is not prescribed Ca/VitD 
supplementation. 
15 4% 15/25 (60%) 
47 The patient is not reminded and proposed to undergo yearly influenza vaccination. 0 0% 0% 
48 The patient is taking methotrexate and is not prescribed folic acid supplementation. 1 0% 1/1 (100%) 
 Part 4: Drug-Drug interactions of specific relevance  
49 VKA + oral NSAIDs 2 1%  
50 RAAS-inhibitor + potassium sparing diuretic/potassium supplements/potassium containing 
drugsb 
20 5%  
51 VKA + Antiplatelet drugs (esp. ASA), unless prescribed by internist/cardiologist 11 3%  
52 VKA + TMP/SMX 0 0%  
53 Oral NSAID + Oral Corticosteroids 4 1%  
54 Oral NSAID + Diuretic 22 6%  
55 Digoxin + Macrolide antibiotics 1 0%  
56 Digoxin + Verapamil/Diltiazem 0 0%  
57 Lithium + RAAS-inhibitors 0 0%  
58 Lithium + Oral NSAID 0 0%  
59 Lithium + Diuretics 0 0%  
60 Theophylline + Quinolones/Macrolides 2 1%  
61 RAAS-inhibitor + Oral NSAID 8 2%  
62 Oral NSAID + SSRI/SNRI 9 2%  
63 RAAS-inhibitor + TMP/SMX 2 1%  
64 Oral antidiabetics/insulin + non-selective beta-blocker 8 2%  
65 Oral antidiabetics/insulin + cardioselective beta-blocker 37 9%  
66 Alprazolam/Midazolam/Triazolam/Zolpidem/Zopiclone + Strong CYP3A4 inhibitor 3 1%  
67 CCB + Strong CYP3A4 inhibitor 0 0%  
68 Oral NSAID + Antipletelet drugs 16 4%  
69 Phenytoin + TMP/SMX 0 0%  
70 First dose RAAS-inhibitor at full dosage + pre-treatment with diuretic 5 1%  
71 Tamoxifen + strong CYP2D6 inhibitors  0 0%  
72 Calcium + Quinolones/Tetracyclines 13 3%  
73 Calcium + Stontium ranelate 5 1%  
74 Calcium + Levothyroxine 10 3%  
75 Bisphosphonate + Calcium, Magnesium, Zinc, Iron or Aluminium 22 6%  
76 VKA + Vitamin K containing drugs/supplementsc 1 0%  
77 Any combination of anticholinergic drug 163 41%  
ASA: Acetylsalicylic acid; BPH: Benign prostatic hyperplasia; CCB: Calcium Channel Blocker; COPD: Chronic Obstructive Pulmonary Disease; CV-
risk: Cardiovascular risk; GI-risk: Gastro-intestinal risk; GP: General Practitioner; NSAID: Non Steroidal Anti-Inflammatory Drug; INR: 
International Normalized Ratio; PPI: Proton Pump Inhibitor; RAAS-inhibitor: Renin-Angiotensin-Aldosteron System Inhibitors; SNRI: Serotonin and 
Noradrenalin Reuptake Inhibitor; SSRI: Selective Serotonin Reuptake Inhibitor; TMP/SMX: Trimetoprim/Sulfamethoxazol; VKA: Vitamin K 
Antagonist. 
 
a Full dose defined as: >20 mg (es)omeprazole, >20mg pantoprazole, >30mg lansoprazole, >20mg rabeprazole  
b Some drugs contain considerable potassium amounts: Glucosamine in potassium salt (up to 300mg/tablet), oral nutritional supplements (up to 
200mg/unit).... (Recommended Daily Dose: 3000mg/day for ≥60 year old patients) 
c Some supplements such as oral nutritional supplements contain considerable Vitamin K amounts (up to 13µg/unit). (Recommended Daily Dose: 
50-70µg/day for ≥60 year old patients) 
 
 
 
